Related Experiment Video
Updated: Feb 24, 2026
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Validation of D-Dimer as a Prognostic Biomarker in Transplant-Associated Thrombotic Microangiopathy in Children
Erin L Frost1, Joel Ofori2, Kirsten M Williams1
1Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA.
Severe transplant-associated thrombotic microangiopathy (TA-TMA), defined as multi-organ dysfunction (MOD), is a life-threatening complication of hematopoietic cell transplantation (HCT). We previously showed that D-dimer is a novel prognostic marker; levels ≥574 mg/L at TA-TMA diagnosis predicted the development of MOD. In this independent cohort of children with TA-TMA (n = 45), D-dimer levels ≥574 mg/L at diagnosis predicted MOD, with a sensitivity of 94.4 (95% confidence interval [CI]: 72.7-99.9) and a specificity of 63.6 (95% CI: 30.8-89.1). Ready availability and low cost make D-dimer a promising marker for predicting patients at risk for developing severe disease and may inform treatment approaches.
Severe transplant-associated thrombotic microangiopathy (TA-TMA), defined as multi-organ dysfunction (MOD), is a life-threatening complication of hematopoietic cell transplantation (HCT). We previously showed that D-dimer is a novel prognostic marker; levels ≥574 mg/L at TA-TMA diagnosis predicted the development of MOD. In this independent cohort of children with TA-TMA (n = 45), D-dimer levels ≥574 mg/L at diagnosis predicted MOD, with a sensitivity of 94.4 (95% confidence interval [CI]: 72.7-99.9) and a specificity of 63.6 (95% CI: 30.8-89.1). Ready availability and low cost make D-dimer a promising marker for predicting patients at risk for developing severe disease and may inform treatment approaches.
Related Concept Videos
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:29Venous Thrombosis III: Interprofessional Care